Latest Breaking News On - Clinical dementia rating scale - Page 5 : comparemela.com

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ Actinogen Medical ASX: ACW ("ACW" or "the Company")is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD2023)later today in Gothenburg, Sweden. Dr Hilt was invited to present Actinogen's novel Phase 2a data as an oral presentation in a symposium session entitled AD Drug Development Clinical Trials. The presentation details the unique longitudinal dataset demonstrating 1) the utility of using the plasma biomarker pTau181 for selection of patients with a more progressive form of mild AD in clinical trials and 2) an encouraging beneficial effect

New south walesVastra gotalands lanSteven gourlayMichael robertsAd drug development clinical trialsInternational conference on alzheimerChief medical officerInternational conferenceDevelopment clinicalClinical dementia rating scaleNeurologic test batteryA longitudinal dataset indicating the utility of plasma ptau for patient selection in clinical trials patients with mild alzheimer 39s disease ad and likely therapeutic benefit oral xanamem this population sydneyMarch 30023 prnewswire actinogen medical asx acw quot or the company is pleased to announce that its chief officerR dana hilt will make an oral presentation to the international conference on alzheimer 39s and parkinson diseases related neurological disorders adpd2023 later today in gothenburgWeden dr hilt was invited to present actinogen 39s novel phase 2a data as an oral presentation ina symposium session entitled ad drug development clinical trials the details unique longitudinal dataset demonstrating 1 utility of using plasma biomarker ptau181 for selection patients witha more progressive form mild in and 2 encouraging beneficial effect xanamem on endpoints function cdr sb cognition ntb these his analyses four studies that have shown positive results acw small molecule pave way 330 person xanamia 2b trial commence coming months key points include most anti amyloid therapies failed recent lecanemab shows onlya modest